Corvus Pharmaceuticals Inc
CRVSHealthcare|Biotechnology|USA
$15.67
-0.53 (-3.27%)
Tangible Book
$2.86
Earnings Power
$2.59
Financials
Financial Snapshot
Market Cap
$1.32B
Enterprise Value
$235.9M
Revenue (TTM)
$0.00
Net Income (TTM)
$-44.2M
Cash & Equivalents
—
Net Cash/Share
$2.67
Free Cash Flow (TTM)
$-35.1M
Operating CF (TTM)
$-34.9M
Debt/Equity
0
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$8.7M
Monthly Burn
$2.9M
Est. Runway
—
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $134.9M | $90.1M | $114.6M | $78.0M | $44.3M | $69.5M | $42.3M | $27.1M | $52.0M | $56.8M | $236.7M | |
| Operating Cash Flow | $-27.9M | $-46.2M | $-41.0M | $-37.3M | $-34.8M | $-36.7M | $-27.0M | $-23.9M | $-25.4M | $-32.8M | $-34.9M | |
| Free Cash Flow | $-30.1M | $-46.5M | $-41.3M | $-37.3M | $-34.9M | $-36.7M | $-27.3M | $-24.0M | $-25.4M | $-33.0M | $-35.1M | |
| Capital Expenditure | $-2.2M | $-266.0K | $-355.0K | $-25.0K | $-76.0K | $-5.0K | $-269.0K | $-34.0K | $0.00 | $-174.0K | $-229.0K | |
| Financing Cash Flow | $71.4M | $1.4M | $65.3M | $24.0K | $1.3M | $62.2M | $0.00 | $7.9M | $49.0M | $36.4M | $226.9M |
R&D Spending
R&D (TTM)
$37.4M
R&D Intensity
—
R&D Growth YoY
+11.0%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $29.4M | $46.3M | $38.6M | $38.0M | $31.8M | $29.1M | $24.5M | $16.5M | $19.4M | $33.7M | $37.4M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | — | — | — | |
| SG&A | $7.6M | $10.2M | $10.6M | $10.9M | $11.9M | $9.5M | $8.1M | $6.9M | $8.2M | $9.3M | $10.5M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $29.4M | $46.3M | $38.6M | $38.0M | $31.8M | $29.1M | $24.5M | $16.5M | $19.4M | $33.7M | $37.4M | |
| SG&A | $7.6M | $10.2M | $10.6M | $10.9M | $11.9M | $9.5M | $8.1M | $6.9M | $8.2M | $9.3M | $10.5M | |
| Operating Income | $-37.0M | $-56.5M | $-49.2M | $-48.9M | $-43.8M | $-38.6M | $-32.6M | $-23.4M | $-27.5M | $-43.0M | $-47.9M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-15.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-36.4M | $-55.7M | $-46.9M | $-46.7M | $-6.0M | $-43.2M | $-41.3M | $-27.0M | $-62.3M | $-15.3M | $-44.2M | |
| Net Income | $-36.4M | $-55.7M | $-46.9M | $-46.7M | $-6.0M | $-43.2M | $-41.3M | $-27.0M | $-62.3M | $-15.3M | $-44.2M | |
| EPS (Diluted) | -2.36 | -2.72 | -1.71 | -1.59 | -0.20 | -1.03 | -0.89 | -0.56 | -1.02 | -0.53 | -0.52 | |
| EBITDA | $-36.4M | $-55.7M | $-48.4M | $-48.1M | $-43.1M | $-38.2M | $-32.2M | $-23.3M | $-27.5M | $-42.9M | $-47.8M | |
| Shares Out. (M) | 15.42 | 20.49 | 27.51 | 29.35 | 29.48 | 41.85 | 46.55 | 48.02 | 60.98 | 79.74 | 90.00 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.0M | $45.1M | $39.2M | $5.2M | $16.5M | $63.5M | $13.2M | $12.6M | $8.7M | $4.6M | $40.1M | |
| Marketable Securities | $129.8M | $44.9M | $75.4M | $72.8M | $27.8M | $6.0M | $29.1M | $14.5M | $43.2M | $52.2M | $196.6M | |
| Total Current Assets | $136.0M | $91.2M | $115.6M | $79.3M | $45.3M | $71.3M | $43.7M | $28.0M | $54.4M | $58.2M | $239.9M | |
| Total Assets | $140.2M | $94.8M | $118.2M | $83.6M | $85.5M | $109.5M | $68.2M | $45.6M | $68.9M | $71.1M | $253.2M | |
| Total Current Liabilities | $5.9M | $9.0M | $7.0M | $10.2M | $12.1M | $9.7M | $10.8M | $6.9M | $35.4M | $9.4M | $12.1M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $7.3M | $9.9M | $7.9M | $12.5M | $13.4M | $12.3M | $12.1M | $6.9M | $36.3M | $9.9M | $12.5M | |
| Stockholders' Equity | $132.8M | $84.8M | $110.3M | $71.1M | $72.1M | $97.2M | $56.1M | $38.7M | $32.6M | $61.2M | $240.7M | |
| Retained Earnings | $-67.9M | $-123.5M | $-170.5M | $-217.1M | $-223.1M | $-266.4M | $-307.7M | $-334.7M | $-397.0M | $-412.3M | $-426.0M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-27.9M | $-46.2M | $-41.0M | $-37.3M | $-34.8M | $-36.7M | $-27.0M | $-23.9M | $-25.4M | $-32.8M | $-34.9M | |
| Capital Expenditure | $-2.2M | $-266.0K | $-355.0K | $-25.0K | $-76.0K | $-5.0K | $-269.0K | $-34.0K | $0.00 | $-174.0K | $-229.0K | |
| Free Cash Flow | $-30.1M | $-46.5M | $-41.3M | $-37.3M | $-34.9M | $-36.7M | $-27.3M | $-24.0M | $-25.4M | $-33.0M | $-35.1M | |
| Investing Cash Flow | $-42.6M | $84.8M | $-30.2M | $3.3M | $44.8M | $21.6M | $-23.3M | $15.5M | $-27.5M | $-7.8M | $-156.9M | |
| Financing Cash Flow | $71.4M | $1.4M | $65.3M | $24.0K | $1.3M | $62.2M | $0.00 | $7.9M | $49.0M | $36.4M | $226.9M | |
| Issuance of Stock | $71.4M | $711.0K | $64.9M | $0.00 | $1.2M | $60.9M | $0.00 | $7.8M | $16.4M | $0.00 | $189.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $3.8M | $6.2M | $7.1M | $7.3M | $5.7M | $4.2M | $2.7M | $2.1M | $3.0M | $5.3M | $6.7M | |
| Net Change in Cash | $945.0K | $40.1M | $-5.9M | $-34.0M | $11.3M | $47.0M | $-50.3M | $-539.0K | $-3.9M | $-4.2M | $35.1M |
Dilution Tracker
Shares outstanding grew 115.0% over 5 years — significant dilution
Shares Outstanding
90M
5-Year Share Growth
+115.0%
Stock Issuance (TTM)
$189.4M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 15.42 | 20.49 | 27.51 | 29.35 | 29.48 | 41.85 | 46.55 | 48.02 | 60.98 | 79.74 | 90.00 | |
| YoY Change % | — | 32.9% | 34.3% | 6.7% | 0.4% | 42.0% | 11.2% | 3.2% | 27.0% | 30.8% | 12.9% | |
| Stock Issuance | $71.4M | $711.0K | $64.9M | $0.00 | $1.2M | $60.9M | $0.00 | $7.8M | $16.4M | $0.00 | $189.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $3.8M | $6.2M | $7.1M | $7.3M | $5.7M | $4.2M | $2.7M | $2.1M | $3.0M | $5.3M | $6.7M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| ROE % | -71.5% | -51.2% | -48.1% | -51.4% | -8.4% | -51.1% | -53.9% | -57.0% | -174.9% | -32.6% | -43.9% | |
| ROA % | -30.5% | -47.4% | -44.1% | -46.2% | -7.1% | -44.4% | -46.5% | -47.5% | -108.8% | -21.8% | -39.9% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S—
Historical— / — / —
Industry Med.9.49
P/B5.48
Historical— / — / 5.48
Industry Med.2.93
EV/EBITDA-22.63
Historical-22.63 / — / —
Industry Med.13.02
EV/Revenue—
Historical— / — / —
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$2.86
Net Current Assets
$2.700
Net-Net Working Capital
$2.67
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | - | - | - | - | - | - | 0.00 | |
| PB Ratio | 2.25 | 2.57 | 0.98 | 2.14 | 1.40 | 1.15 | 0.71 | 2.23 | 11.15 | 9.40 | 5.48 | |
| EV/EBITDA | -4.52 | -2.30 | 0.14 | -1.61 | -1.37 | -1.22 | 0.00 | -2.60 | -11.38 | -12.12 | -22.63 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
4
Moderate
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $0.00M | $8.45M | $42.88M |
| Net Income | $-61.58M | $-78.45M | $-72.62M |
| EPS | -0.69 | -0.86 | -0.63 |
| Book Value per Share | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow per Share | 0.00 | 0.00 | 0.00 |
| Operating CF | $0.00M | $0.00M | $0.00M |